ADAPTIVE BIOTECHNOLOGIES CORPORATION Contract Liability (Deferred Revenue)
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Contract Liability (Deferred Revenue) of $53.26 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-04
- 2026-06-30: Contract with Customer, Liability, Current $53.26M.
- 2026-03-31: Contract with Customer, Liability, Current $49.40M.
- 2025-12-31: Contract with Customer, Liability, Current $45.19M.
- 2025-09-30: Contract with Customer, Liability, Current $41.34M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $53.26M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $49.40M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $45.19M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $41.34M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $55.30M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $54.80M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $55.69M 10-K · filed 2026-02-26 |
| 2024-09-30 | $51.86M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $52.23M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $46.87M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $48.63M 10-K · filed 2025-03-03 |
| 2023-09-30 | $55.34M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $57.92M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $60.32M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $64.11M 10-K · filed 2024-02-29 |
| 2022-09-30 | $67.89M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $80.91M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $83.50M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $80.46M 10-K · filed 2023-02-14 |
| 2021-09-30 | $79.95M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $83.55M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $78.35M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $73.32M 10-K · filed 2022-02-15 |
| 2020-09-30 | $78.19M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $75.70M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $64.57M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $60.99M 10-K · filed 2021-02-24 |
| 2019-09-30 | $61.27M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $61.19M 10-Q · filed 2019-08-13 |
| 2018-12-31 | $12.70M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |